Editas Medicine, Inc. (EDIT) Stock

Editas Medicine, Inc. (EDIT) is a Healthcare stock trading at $2.68 (as of 2026-06-18), with a market capitalization of $338.76M and a trailing P/E of -2.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Editas Medicine, Inc. is a clinical-stage genome editing company that uses a CRISPR-based platform to develop gene-based therapies for diseases including inherited retinal disorders and other conditions. Its pipeline includes EDIT-101 (Phase 1/2 for Leber congenital amaurosis 10) and EDIT-102 for Usher syndrome 2A, and it also develops additional oncology cell therapies and partnered research programs.

Valuation — source: SEC EDGAR (first-party)
Price	$2.68
Market Cap	$338.76M
P/E Ratio	-2.4
EV / EBITDA	-1.8
Price / Book	59.75
Price / Sales	6.81
DCF Value (model)	$-27.92
DCF Upside vs Price	-1141.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$40.52M
Net Margin	-395.0%
Return on Equity	-2471.7%
Debt / Equity	12.40
Current Ratio	3.22
Revenue Growth (YoY)	25.4%
EPS Growth (YoY)	-37.5%
FCF Growth (YoY)	-24.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-13.09 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-111.3%
vs Industry	-113.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($22.88M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Gilmore O'Neill
Employees	246
Country	US
IPO Date	2016-02-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.